Alphabet, Sanofi and Syncona were among the investors helping the drug developer advance toward clinical trials.

OMass Therapeutics, a UK-based small molecule drug developer, is taking novel treatments for inflammatory bowel disease and adrenal conditions to clinical trials with the help of a $100m series B round co-led by internet and technology group Alphabet and pharmaceutical firm Sanofi.

Founded in 2016 and spun out of University of Oxford, OMass has developed a drug discovery platform, called OdyssION, that uses mass spectrometry and custom chemistry to precisely track targets such as complex-bound proteins, solute carriers and G-protein-coupled-receptors…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.